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1. Introduction 
Embryonic stem (ES) cells are a rich source of multiple different cell types of diverse 
lineages. Significant advances have recently been made in our understanding of the 
molecular mechanisms by which ES cells differentiate into endothelial cells. The 
differentiation of ES cells into endothelial cells can be enhanced by certain growth factors, 
environmental cues, cell-cell interactions, and extracellular matrix. A wide variety of signal 
transduction pathways and transcription factors have been shown to participate in this 
process. The use of ES cells for endothelial differentiation are not only of interest with 
respect to the molecular mechanisms but also for identifying sources of endothelial cells that 
can be used for a number of therapeutic purposes. The purpose of this chapter is to review 
recent advances in the molecular mechanisms underlying ES differentiation into endothelial 
cells and how endothelial cells derived from ES cells are being used therapeutically.  
2. Culture conditions 
ES cells are derived from the inner cell mass of a growing blastocyst 1. As such, they have 
the capacity to differentiate into all the cell types of an organism 2. To maintain their 
undifferentiated state ES cells are generally grown in the presence of feeder cells or 
leukemia inhibitory factor (LIF). In the absence of inhibitory factors ES cells can 
spontaneously differentiate into cells with characteristics of one of three germ layers; 
mesoderm, endoderm, or ectoderm.  A variety of approaches have been used to differentiate 
human and mouse ES cells that include: (1) aggregating ES cells into three-dimensional cell 
masses called embryoid bodies (EBs); (2) by co-culturing the ES cells with other cell types; 
and (3) by culturing the ES cells on specific matrix surfaces together with defined media.     
Murine ES cells have been used for several years to study differentiation along multiple 
lineages. Culturing ES cells into EBs has been the most frequently used model to study EC 
differentiation. The appearance of structures consisting of immature hematopoietic cells 
surrounded by endothelial cells and the formation of vascular-like channels suggests that 
the EBs produce factors necessary not only for endothelial differentiation but also for 
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vasculogenesis. These structures closely resemble the so-called blood islands of the yolk sac. 
One of the major advantages of this culture method is the highly reproducible timing of 
molecular events that occurs during the process of differentiation. The induction of both 
hematopoietic and endothelial markers at precise time points during the differentiation has 
greatly facilitated investigation of factors that promote or inhibit EC differentiation or 
hematopoiesis. Their close association has also led to commonly held belief that the 
hematopoietic and endothelial lineages stem from a common precursor known as the 
hemangioblast. The markers of hematopoiesis and endothelial differentiation also permit 
the isolation of specific populations of cells at different stages of differentiation. An example 
of one of the earliest markers of the endothelial lineage is VE-cadherin, and of the 
hematopoietic lineage is CD41. One of the potential disadvantages of this model is that only 
a fraction of the cells, on the order of 5-10%, ultimately become endothelial cells.  
Human ES cells have also been used to generate EBs as a model of EC differentiation or 
hematopoiesis. endothelial cells can be isolated and propagated from human EBs at vary 
time points during differentiation. The EBs can also be used as a model of angiogenesis in 
addition to EC differentiation and vasculogenesis.  11-day old EBs are cultured within three 
dimensional type 1 collagen matrix gels that is supplemented with angiogenic growth 
factors including VEGF and FGF2 3.  The sprouting of new vessels can be observed radiating 
out from the EBs into the surrounding matrix.  
A second mouse model of ES cell differentiation is a two dimensional system that takes 
advantage of the calvaria stromal cell line OP9. ES cells are initially grown as EBs and then a 
subset of cells expressing VEGF-R2 are separated by flow cytometry. These VEGF-R2 cells 
are grown on the OP9 cells they gradually differentiate into endothelial cells expressing VE-
cadherin and CD31 (PECAM-1).  Interestingly, the endothelial cells exhibited two 
morphological characteristics. On the one hand endothelial cells grew as sheets of cells and 
on the other hand the cells coalesced into cord-like structures. It was determined that the 
sheet-like Endothelial cells were of lymphatic origin, whereas the other endothelial cells 
were more like blood endothelial cells. Two soluble factors made by the OP9 cells that 
contribute to the differentiation of these cells into lymphatic endothelial cells include 
Angiopoietin-1 and VEGF-C.  
A third method of culturing the murine ES cells into endothelial cells consists of isolating a 
subpopulation of ES cells that express the VEGF receptor 2 (VEGF-R2) and allowing them to 
differentiate on an acellular matrix such as type IV collagen 4. By adding growth factors to a 
serum free media it was determined that VEGF was a critical factor for differentiating 
VEGF-R2 expressing ES cells into endothelial cells.  
3. Markers of the endothelial lineage 
A critical determinant of endothelial differentiation is the identification of selective markers 
that separate the endothelial lineage from other lineages. Because of the close association 
between the hematopoietic and the endothelial lineage, the existence of a bipotent cell called 
the hemangioblast capable of differentiating into either the endothelial or hematopoietic 
lineages was suggested and identified 5,6. A commonly used marker to define this cell type is 
the VEGF receptor 2 (VEGF-R2). Using an embryoid body (EB) model of ES the temporal 
expression pattern of several endothelial markers was evaluated by PCR and 
immunohistochemistry 7. The expression of VEGF-R2 on day three of differentiation 
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preceded the expression of all of the endothelial markers. The expression of PECAM-1, Tie-
1, Tie2, and VE-cadherin, followed shortly thereafter on days 4 and 5 of differentiation. 
Furthermore, the number of cells expressing these EC-specific markers represented a small 
fraction of the overall number of ES cells that appeared to coalesce into discreet regions of 
the EBs and by day 12 of differentiation when they formed primitive vascular structures. 
The number of cells expressing the endothelial marker PECAM-1 was enhanced by adding 
the growth factor VEGF on day 6 of ES cell differentiation 7.  We have similarly used the 
embryoid body model to identify a population of VEGF-R2 expressing mouse embryonic 
stem cells that also express the endothelial marker VE-cadherin and that are distinct from 
those that express the hematopoietic marker CD41 8. 
The close association between the hematopoietic and endothelial lineages that is seen during 
ES cell differentiation has also been observed in a variety of different organisms including 
the mouse, chicken, zebrafish and humans during embryonic development. In the mouse for 
example, cells of the hematopoietic and endothelial lineages are first observed in the yolk 
sac in regions called blood islands. In addition to the yolk sac, the generation of blood is first 
observed in the developing embryo in a region called the aorta-gonad-mesonephros (AGM), 
in the vitelline and umbilical arteries, and in the allantois/placenta region 9 10,11. In the AGM 
region hematopoietic cells are found in close association with the endothelial wall of the 
aorta suggesting that these early hematopoietic cells are generated from an early 
intermediate called the hemogenic endothelium 9,12. Additional support for the hemogenic 
endothelium has come from in vitro studies of mouse embryonic stem cell differentiation. 
Blast colony-forming cells (BL-CFCs) were identified that can give rise to cells of both the 
endothelial and hematopoietic lineages 5,6. More recently, studies using time-lapse 
photography and FACS analysis of differentiating mouse embryonic stem cells, have 
demonstrated that the hemangioblast generates hematopoietic cells through the formation 
of a hemogenic endothelium intermediate 13. In particular, Tie2hic-Kit+CD41- expressing cells 
were identified as a population of cells that constitute the hemogenic endothelium. 
Further differentiation of endothelial cells into cells of arterial, venous, and lymphatic 
endothelium has also been shown to occur in ES cells and do so in the developing embryo 
prior to the development of blood flow. The differentiation of embryonic stem cells into 
arterial endothelial cells is dependent on the presence and concentration of VEGF. When 
mouse ES cells are cultured in the presence of lower molecular weight isoforms of VEGF 
(120 and 164) they differentiate into endothelial cells expressing arterial markers 14. The 
differentiation of ES cells into arterial versus venous endothelial cells is also dependent on 
the dose of VEGF. Whereas at low concentration of VEGF (2ng/ml) cultured VEGF-R2 
expressing mouse ES cells differentiate into endothelial cells expressing venous EC markers 
such as neuropilin-2 (NRP2), at higher concentrations of VEGF (50 ng/ml) the same cells 
will differentiate into EC expressing the arterial markers Ephrin B2 and neuropiin-1 (NRP1) 
15. ES cells have also been used study their differentiation into lymphatic endothelial cells. 
For example, murine ES cells were aggregated to form EBs and then were cultured in a 3-
dimensional collagen matrix for up to 18 days 16. Treatment with a combination of growth 
factors including VEGF-C and VEGF-A enhanced the formation of lymphatic endothelial 
cells in the EBs 17. An alternative approach of promoting the differentiating ES cell along the 
lymphatic lineage is to use VEGF-R2 expressing ES cells and to co-culture them with OP9 
stromal cells 18. The differentiation of the VEGF-R2 cells into lymphatic endothelial cells is 
dependent upon VEGF-C and angiopoietin-1. 
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4. Signal transduction pathways 
A variety of signal transduction pathways have been implicated during the process of 
endothelial differentiation. At the top of the hierarchy of signal transduction molecules are 
the hedgehog (HH) family of signaling proteins, which play a number of different roles in 
determination of cell fate, embryonic patterning, and morphogenesis 19.  HH signaling 
activates the transcription factor GLI.  Inhibition of Indian hedgehog (IHH) during the 
differentiation of mouse or human ES cells blocks their ability to differentiate along the 
endothelial and hematopoietic lineages 20 21.  In addition to IHH, several studies have 
suggested a role for sonic hedgehog (SHH) in endothelial differentiation. In the absence of 
SHH, angioblasts fail to form into EC tubes or vascular networks 22. Administration of SHH 
was able to promote the differentiation of human multipotent adult progenitor cells into 
arterial endothelial cells both in vivo and in vitro 23.  
Bone morphogenic proteins (BMPs) belong to the TGF-beta family of proteins that are 
involved in regulating cell proliferation, survival, and differentiation during embryogenesis 
24. In particular, BMP-2 and BMP-4 are known mediators of endothelial function and 
differentiation during embryogenesis and ES cell differentiation 25,26. BMP appears to 
function downstream of the HH proteins during the in vitro differentiation of ES cells along 
the EC lineage. Inhibition of EC differentiation by blocking the HH pathway can be rescued 
with BMP-4 20. Furthermore, when human ES cells are cultured in the presence of BMP-4, 
this augments their differentiation along the endothelial lineage 25.  
BMPs can also activate a number of downstream signal transduction pathways. For 
example, the induction of angiogenesis by BMP-2 is dependent upon activation of the 
canonical and non-canonical WNT pathways 26. BMPs can also activate the MAP kinase 
signaling pathways.  For example, BMP-4 activation of EC sprouting is dependent upon p38 
MAP kinase 27. Inhibition of EC migration by BMPs is dependent upon the JNK and ERK 
pathways 28. In contrast to BMP-2 and BMP-4, two BMPs, BMP-9 and BMP-10 inhibit the 
growth of endothelial cells and promote endothelial quiescence 29,30. The role of BMP-9 and 
BMP-10 in endothelial differentiation has not been studied, however in contrast to other 
endothelial cells, BMP-9 promotes the proliferation of mouse embryonic-stem cell derived 
endothelial cells 31. 
WNT signaling is involved in processes that determine cell fate, self-renewal of stem cells, 
polarity, and organogenesis.  There are three classical WNT pathways: (1) the canonical or 
WNT/-catenin pathway; (2) the planar cell polarity pathway; and (3) the WNT/Ca2+ 
pathway 32. WNT5A is a mediator of EC proliferation, survival, and differentiation. WNT5A 
is expressed in the developing vasculature of several organs including the skin, retina, 
stomach, and liver 33. WNT5A functions predominantly through the non-canonical WNT 
pathways. Signaling cascades activated by WNT5A include the protein kinase C (PKC) and 
c-Jun n-terminal kinase (JNK) pathways 34. WNT5A can also inhibit the activity of the 
canonical WNT/-catenin pathway 35. WNT5A contributes to the regulation of the 
differentiation of ES cells along the endothelial lineage 36. WNT5A deficient ES cells cannot 
differentiate into endothelial cells. In endothelial cells WNT5A can activate both the 
canonical and non-canonical WNT pathways. The WNT/Ca2+ pathway is the predominant 
WNT pathway activated in WNT5A deficient ES cells exposed to exogenous WNT5A.  A 
role for WNT signaling has also been evaluated during the differentiation of the 
hemangioblast in human ES cells 37.  Administration of the WNT inhibitor dickkopf1 
markedly inhibited the differentiation of ES cells towards the endothelial or hematopoietic 
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lineages. Likewise, when ES cells were cultured in the presence of WNT1, there was a marked 
increase in the number of hemangioblast like cells. In contrast, when ES cells were exposed to 
WNT5A, they did not have the same effect of increasing the number of hemangioblasts, 
suggesting that WNT5A principally acts at later stages of EC differentiation 38.  
5. Transcription factors 
A variety of transcription factors are known to play a critical role in cellular differentiation 
during embryonic development. In particular, selected transcription factors are known to 
regulate the differentiation of embryonic stem along the endothelial or hematopoietic 
lineages. As mentioned above, the hemangioblast is a bipotent cell capable of differentiating 
into either endothelial or hematopoietic cells. The basic helix-loop-helix (HLH) transcription 
factor SCL (Tal1) has been shown to be critical for blood and endothelial cell development 39. 
SCL is expressed early during embryogenesis in hematopoietic and endothelial cells and its 
disruption in either mouse or zebrafish leads to severe defects in vasculogenesis 40-42. SCL is 
also an early marker of the hemangioblast in embryonic stem cells during their 
differentiation towards the hematopoietic and endothelial lineages 43. In this model of ES 
cells were cultured in serum free conditions and sequentially exposed to BMP4, activin A, 
bFGF, and VEGF. As the mesodermal marker brachyury gradually decreases there is an 
increase in the expression of SCL together with two other transcription factors Runx1 and 
Hhex. SCL deficient ES cells are unable to generate either primitive or definitive 
hematopoietic cells 44. SCL also appears to be critical for the development of the hemogenic 
endothelium 13. SCL deficient ES cells failed to differentiate into Tie2hic-Kit+CD41- cells that 
constitute cells with the capacity to differentiate into hematopoietic and endothelial cells. 
Members of the ETS family of transcription factors have also been shown to play a role in 
the regulation of EC-specific gene expression and EC differentiation.  For example, ER71 has 
been shown to be critical for endothelial differentiation and vascular development in mice 
and zebrafish 45,46. In ES cells ER71 is critical for the expression of VEGF-R2 47.  ER71 appears 
to induce VEFGF-R2 downstream of BMP, Notch, and Wnt signaling. Another ETS factor 
that is expressed in the vasculature and regulates hematopoiesis is Fli-1. Fli-1 deficient mice 
die at embryonic day E12.5 of defective vasculogenesis leading to cerebral hemorrhage 48. 
Fli-1 deficient ES cells also exhibit defective hematopoiesis with a marked reduction in the 
number of blast colony forming cells. In contrast to most other ETS factors we and other 
groups have shown that the ETS factor ERG exhibits an EC-restricted expression pattern 49-
52. Furthermore, it has also been shown that several EC-restricted genes including VE-
cadherin, endoglin, and vWF, are regulated by ERG 53-55. In addition to its role in regulating 
EC-restricted genes we have recently shown that ERG is critical effector of EC differentiation 
of ES cells that appears to be independent of hematopoiesis 56. ERG was selectively 
expressed in VEGF-R2+VE-caherin+ cells and not in VEGF-R2+CD41+ cells. Suppression of 
ERG in ES cells by lentivirally delivery of shRNA resulted in a significant reduction in EC 
differentiation but not hematopoietic cells. 
There are several transcription factors that facilitate the differentiation of ES cells into 
arterial, venous, and lymphatic endothelial cells. The critical transcription factor that 
promotes the differentiation of the hemangioblast or VEGF-R2 expressing cells into venous 
endothelial cells is COUP-TFII 15. The differentiation of these cells was dependent upon the 
dose of VEGF. Whereas low doses of VEGF (2-10 ng/ml) induced the differentiation of 
VEGF-R2 cells into venous endothelial cells expressing high levels of COUP-TFII, high doses 
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of VEGF (50 ng/ml) repressed COUP-TFII levels and induced the differentiation of VEGF-
R2 cells into endothelial cells expressing markers of arterial endothelial cells such as Ephrin 
B2. Transcription factors that are preferentially upregulated in arterial endothelial cells 
include the HLH factors Hey1 and Hey2. Notch signaling appears to be critical for 
promoting differentiation of ES cells into arterial endothelial cells. Inhibition of Notch 
signaling with a gamma secretase inhibitor preferentially leads to the expression of venous 
EC markers and a repression of arterial markers 15. An environmental stimulus that 
promotes the differentiation of ES cells into arterial endothelial cells is hypoxia. Exposure of 
ES cells to hypoxia was associated with an increase in the expression of the Notch ligand 
Dll4 and the transcription factors Hey1 and Hey2 57. 
The prototypic transcription factor that regulates the differentiation of ES cells into 
lymphatic endothelial cells is Prox1.  Prox1 expression can be induced by three-dimensional 
culture of murine ES cells into EBs in collagen matrices in the presence of VEGF-C and 
VEGF-A 16. Similarly when VEGF-R2 cells were co-cultured with OP9 cells expression of 
Prox1 was observed in lymphatic endothelial cells on day 3 18. Expression of Prox1 in blood 
endothelial cell leads expression of lymphatic markers and transdifferentiation into 
lymphatic endothelial cells 58. Another transcription factor that regulates the expression of 
the VEGF-R3, which binds to VEGF-C, is the T box transcription factor Tbx1 59. Although 
Tbx1 is not required for LEC differentiation it is required for the growth and maintenance of 
lymphatic vessels. A transcription factor that is involved in regulating later stages of 
lymphatic EC maturation is the forkhead transcription factor Foxc2 60,61. Foxc2 was shown to 
be important for the development of lymphatic valves and controlling interactions between 
lymphatic endothelial cells and mural cells.  
6. Therapeutic implications 
One of the ultimate goals of developing culture methods that promote the differentiation of 
stem cells into endothelial cell is to provide a source of cells for a variety of different 
therapeutic applications. One obvious application would be to generate new blood vessels 
or repair existing blood vessels in clinical settings where blood flow is compromised. As an 
initial proof of concept a population of VEGF-R2 expressing mouse ES cells were injected 
into chicken embryo hearts. These cells were shown to be able to integrate into the host 
vasculature and differentiate into two cellular components of the vasculature, endothelial 
cell and smooth muscle cells 62. Based on these promising studies embryonic stem cell 
derived endothelial cell have been used in animal models of human disease to promote 
angiogenesis and ultimately improve blood flow. For example, murine ES cell derived 
endothelial cell were injected either intramuscularly or intra-arterially in a hindlimb model 
of ischemia, and were shown to engraft at the site of ischemia and improve tissue perfusion 
63. One of the concerns of using ES cells for therapeutic purposes is the potential formation 
of teratomas from undifferentiated ES cells. In the hindlimb ischemia study no teratomas 
formed when ES cell derived endothelial cell were used compared to their uniform 
development within two weeks when undifferentiated ES cells were used. A similarly 
promising study was done using human ES cell (hESC) derived endothelial cells 64. The 
hESC derived endothelial cells were shown to engraft into blood vessels at sites of 
myocardial ischemia using a mouse myocardial infarction model. Together these exciting 
proof-of-concept studies provide evidence that ES cell derived endothelial cells can be used 
in a variety of settings to promote blood vessel growth at sites of ischemia. One of the major 
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challenges in using the currently available stem cells as a source of endothelial cells for 
therapeutic applications is the potential of significant immune responses to the engrafted 
cells. One potential mechanism of overcoming this hurdle more recently is the development 
of induced pluripotent stem (iPS) cells in which skin fibroblasts from any individual can be 
transformed into ES cells by introducing four transcription factors 65. These iPS cells have 
subsequently been cultured to promote their differentiation into vascular cells that are very 
similar to those obtained from human ES cells 66.  
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